FDA grants breakthrough therapy certification of Bristol Myers Squibb monoclonal antibody elotuzumab

Source: Biovalley 2014-05-20 Bristol Myers Squibb (BMS) and abbvie announced on May 19 that the FDA has granted the experimental monoclonal antibody elotuzumab breakthrough therapy certification Elotuzumab is a humanized monoclonal antibody, which is currently being investigated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma patients who have previously received one or more therapies The award of the breakthrough treatment was based on findings from a randomized, development label phase II study This study evaluated two doses of elotuzumab combined with lenalidomide and low-dose dexamethasone for the treatment of multiple myeloma patients Elotuzumab is a humanized IgG1 monoclonal antibody, targeting the member of the signaling lymphocyte activating molecule family 7 (slamf7, also known as CS1), which is a glycoprotein expressed in myeloma and natural killer (NK) cells, but not detected in normal tissues At present, Bristol Myers and Aberdeen are investigating elotuzumab as a single drug therapy for smoky myeloma, as well as elotuzumab combined with other drugs for the first-line treatment of relapsed or refractory multiple myeloma English Original: Bristol Myers Squibb and abbvie receive U.S FDA break through therapy design for elotuzumab, an investigative humanized monolonal antibody for multiple myeloma